Belantamab-Mafodotin (4) – Blenrep®
Multiple myeloma, relapsed or refractory, following at least one prior course of treatment; combination with pomalidomide and dexamethasone
Characteristics
| Start date | 01.04.2026 |
|---|---|
| Resolution | 01.10.2026 – active procedure |
| INN | Belantamab-Mafodotin |
| Brand name | Blenrep® |
| Pharm. company | GlaxoSmithKline GmbH & Co. KG |
| G-BA Procedure ID | D-1244 |
| Therapeutic area | Oncological diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Belantamab-Mafodotin (4) | Blenrep® | GlaxoSmithKline GmbH & Co. KG | Multiple myeloma, relapsed or refractory, following at least one prior course of treatment; combination with pomalidomide and dexamethasone | n.d. | active procedure | |
| Belantamab-Mafodotin (3) | Blenrep® | GlaxoSmithKline GmbH & Co. KG | Multiple myeloma, relapsed or refractory, following at least one prior course of treatment; combination therapy with bortezomib and dexamethasone | n.d. | active procedure | |
| Belantamab-Mafodotin (2) | Blenrep® | GlaxoSmithKline GmbH & Co. KG | Multiple myeloma, at least 4 prior therapies, monotherapy |
0
570–1,130 |
100% Hint for non-quantifiable additional benefit Orphan repealed | |
| Belantamab-Mafodotin (1) | Blenrep® | GlaxoSmithKline GmbH & Co. KG | Multiple myeloma (MM), at least 4 prior therapies, monotherapy |
0
570–1,130 |
100% Hint for non-quantifiable additional benefit Orphan repealed |
<< List of all resolutions